Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visible Genetics, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Private placement of 1.9 mil. shares with U.S. and European institutional investors raises $28.7 mil. A portion of the funds will be used to gear up U.S. marketing and manufacturing efforts for the TruGene HIV-I genotyping kit, an FDA regulatory submission for which is anticipated in the first half of 2000 (1"The Gray Sheet" Dec. 6, p. 14). The proceeds will be directed toward new product development and for general working capital, the Toronto firm says

You may also be interested in...



Visible Genetics Preparing TruGene HIV Genotyping Assay FDA Submission

Visible Genetics, Inc. is looking to file an FDA application for its TruGene HIV genotyping assay kit in the first half of 2000, the company reported Nov. 30 at a BancBoston Robertson Stephens health care conference in New York City.

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.

UsernamePublicRestriction

Register

LL1129552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel